Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Duska Therapeutics Completes Corporate Name Change to Cordex Pharma

January 28, 2009

Stock to trade under new ticker symbol ‘CDXP.OB’

LA JOLLA, Calif., Jan. 28 /PRNewswire-FirstCall/ — Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA) announced today that it has completed a corporate name change to Cordex Pharma, Inc. As a result of the name change, the Over-the-Counter Bulletin Board will trade the Company’s common stock under the ticker symbol OTCBB: CDXP.OB.

James S. Kuo, M.D., Cordex’s Chief Executive Officer commented, “We are pleased to have completed our corporate name change and selected a new ticker symbol. The Cordex name was chosen for two primary reasons. First, ‘cor’ is the Latin word for heart, which is the focus of our drug development efforts. Second, Cordex is an intentional derivation of ‘codex’, the Latin word for book. Before printing presses, handwritten codices were the repository of all human knowledge. Through our two late-stage clinical programs, we intend to write a new chapter in the development of proprietary pharmaceuticals that treat urgent medical needs.”

In addition to the name change and new ticker symbol, Cordex announced several other corporate changes. The Company has appointed MorisonCogen, LP of Bala Cynwyd, PA, as its independent auditors for the year ending December 31, 2008. Cordex also appointed DirectTransfer, LLC as its stock transfer agent, effective immediately.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex is developing a portfolio of investigational medicines, two of which are in late stages of clinical trials. Cordex’s ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia early in 2009. Cordex’s CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure early in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company’s website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding ATPace’s expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050′s expected commencement of a Phase 2 clinical trial for the treatment of heart failure and our intent to write a new chapter in the development of proprietary pharmaceuticals that treat urgent medical needs. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex’s most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Cordex on the date hereof. Cordex undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.

SOURCE Duska Therapeutics, Inc.; Cordex Pharma, Inc.


Source: newswire